Christie Hospital

The trials here

What the 31 trials at this site are about, from their registry records.

Conditions

• Lung cancer11 trials
• Childhood cancers6 trials
• Colorectal cancer3 trials
• Gastric and oesophageal cancer3 trials
• Head and neck cancer3 trials
• Prostate cancer3 trials
• Diffuse large B-cell lymphoma2 trials
• Hodgkin lymphoma2 trials
• Ovarian cancer2 trials
• Cervical cancer1 trial
• Chronic lymphocytic leukaemia1 trial
• Kidney cancer1 trial
• and 9 more

Phase

• Phase 314 trials
• Phase 28 trials
• Phase 1/23 trials
• Phase 12 trials
• Phase 2/32 trials

Status

• Active, not recruiting20 trials
• Completed6 trials
• Recruiting3 trials
• Terminated2 trials

Lead sponsor

• Amgen7 trials
• University College, London6 trials
• University of Birmingham3 trials
• Daiichi Sankyo2 trials
• Alliance for Clinical Trials in Oncology1 trial
• and 12 more

Running trials

• Active, not recruiting

  A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC

  NCT06745323· Phase 2· Amgen· Source

• Recruiting

  Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma

  NCT05635162· Phase 2· University College, London· Source

  Contact: Kim Linton

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Recruiting

  Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma

  NCT05655078· University College, London· Source

  Contact: Klara Sinalova

• Active, not recruiting

  Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)

  NCT06117774· Phase 3· Amgen· Source

• Active, not recruiting

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· Phase 3· Amgen· Source

• Recruiting

  Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

  NCT04685616· Phase 3· University College, London· Source

  Contact: Beth Phillips

• Active, not recruiting

  A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)

  NCT05060016· Phase 2· Amgen· Source

• Active, not recruiting

  Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)

  NCT04704934· Phase 3· Daiichi Sankyo· Source

• Active, not recruiting

  A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

  NCT04408638· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

  Contact: Martin McCabe

• Active, not recruiting

  A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

  NCT04181827· Phase 3· Janssen Research & Development, LLC· Source

• Active, not recruiting

  A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome

  NCT03899337· Phase 2· University of Birmingham· Source

• Active, not recruiting

  Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

  NCT03319940· Phase 1· Amgen· Source

• Active, not recruiting

  Stereotactic Ablative Radiotherapy for Oligometastatic Non-small Cell Lung Cancer

  NCT02417662· University College, London· Source

• Active, not recruiting

  Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours

  NCT02804815· Phase 3· University College, London· Source

• Active, not recruiting

  Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

  NCT02375204· Phase 3· Alliance for Clinical Trials in Oncology· Source

• Active, not recruiting

  CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

  NCT04116047· Phase 3· University of Birmingham· Source

• Active, not recruiting

  Safety of a Boost (CXB or EBRT) in Combination With Neoadjuvant Chemoradiotherapy for Early Rectal Adenocarcinoma

  NCT02505750· Phase 3· Centre Antoine Lacassagne· Source

• Active, not recruiting

  Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

  NCT01992952· Phase 1/2· Velindre NHS Trust· Source

• Active, not recruiting

  Prostate Advances in Comparative Evidence

  NCT01584258· Phase 3· Royal Marsden NHS Foundation Trust· Source

• Active, not recruiting

  Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy

  NCT00268476· Phase 2/3· Medical Research Council· Source

• Active, not recruiting

  PET Scan in Planning Treatment in Patients Undergoing Combination Chemotherapy For Stage IA or Stage IIA Hodgkin Lymphoma

  NCT00943423· Phase 3· University College, London· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers2 recruiting
• Hodgkin lymphoma1 recruiting
• Mantle cell lymphoma1 recruiting
• Sarcoma1 recruiting

Closed trials

• Terminated

  A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression

  NCT05325866· Phase 1/2· Amgen· Source

• Completed

  A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

  NCT04907539· Phase 2· Redx Pharma Ltd· Source

• Terminated

  Open-Label Surufatinib in European Patients With NET

  NCT04579679· Phase 2· Hutchmed· Source

• Completed

  Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

  NCT04303780· Phase 3· Amgen· Source

• Completed

  DS-8201a in HER2-positive Gastric Cancer That Cannot Be Surgically Removed or Has Spread (DESTINY-Gastric02)

  NCT04014075· Phase 2· Daiichi Sankyo· Source

• Completed

  A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer

  NCT04069026· Phase 1· Bayer· Source

• Completed

  Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

  NCT03173560· Phase 2· Eisai Inc.· Source

• Completed

  Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

  NCT02101788· Phase 2/3· National Cancer Institute (NCI)· Source